Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Autism Treatment & Management

  • Author: James Robert Brasic, MD, MPH; Chief Editor: Caroly Pataki, MD  more...
 
Updated: Dec 01, 2015
 

Approach Considerations

Individual intensive interventions, including behavioral, educational, and psychological components, are the most effective treatments of autistic disorder. Beginning the treatment early in infancy increases the likelihood of a favorable outcome. Thus, regular screening of infants and toddlers for symptoms and signs of autistic disorder is crucial because it allows for early identification of these patients.

Individuals with autism spectrum disorder and unspecified pervasive developmental disorder typically benefit from behaviorally oriented therapeutic programs developed specifically for this population. Autistic children should be placed in these specialized programs as soon as the diagnosis is entertained.

Parents, teachers, pediatricians, and other health care providers are advised to seek the assistance of people who are familiar with early intervention programs for children with autistic disorder. The Autism Society can help parents to obtain appropriate referrals for optimal interventions.

Parents understandably become exhausted by the relentless performance of challenging behaviors by their child with autism. A specially trained educator or behavioral psychologist can help to teach them effective ways to modify these challenging behaviors. Parents also frequently benefit from temporary respite from the child.

The possible benefits from pharmacotherapy must be balanced against the likely adverse effects on a case-by-case basis. In particular, venlafaxine may increase high-intensity aggression in some adolescents with autism.[6]

Limited, largely anecdotal evidence suggests that dietary measures may be helpful in some children with autism. Avoidance of certain foods, notably those containing gluten or casein, and supplementation with specific vitamins and minerals have reportedly proved helpful in select cases.

The National Autism Center has initiated the National Standards Project, which has the goal of establishing a set of evidence-based standards for educational and behavioral interventions for children with autism spectrum disorders. The project has identified established, emerging, and unestablished treatments.

Inpatient Psychiatric Care

In December 2015, an expert panel released 11 consensus statements on best practices for inpatient care of children with autism. The panel recommends that children with ASD or intellectual disability (ID) can be treated in general inpatient psychiatric units, with specific accommodations. The recommendations also set out the information that should be obtained from children on admission, including the child's preferences, means of communication, reinforcement items, sensory sensitivities, etc. Also emphasized is the importance of screening for co-occurring medical and psychiatric conditions.[118]

 

Next

Special Education

Special education is central to the treatment of autistic disorder. Although parents may choose to use various experimental treatments, including medication, they should concurrently use intensive individual special education by an educator familiar with instructing children who have autistic disorder or a related condition. Intensive behavioral interventions, instituted as early as possible, are indicated for every child in whom autistic disorder is suspected[119, 120] .

The Education for All Handicapped Children Act of 1975 requires free and appropriate public education for all children, regardless of the extent and severity of their handicaps. Amendments to the Education of the Handicapped Act of 1986 extended the requirement for free and appropriate education to children aged 3-5 years.

Pediatricians and parents cannot assume, however, that their community’s school will provide satisfactory education for a child with autistic disorder or a related condition. The Individuals with Disabilities Education Act authorized states to determine how to provide educational services to children younger than 3 years. Pediatricians and parents need to determine the best way to proceed with local agencies.

Legal assistance may be necessary to influence a board of education to fund appropriate education for a child with autistic disorder or a related condition. The Autism Society maintains a Web site and offers a toll-free hotline (1-800-3-AUTISM/1-800-328-8476). This resource provides information and referral services to the public.

Previous
Next

Speech, Behavioral, Occupational, and Physical Therapies

Therapies that are reported to help some individuals with autism include the following:

  • Assisted communication - Using keyboards, letter boards, word boards, and other devices (eg, the Picture Exchange Communication System [121] ), with the assistance of a therapist
  • Auditory integration training - A procedure in which the individual listens to specially prepared sounds through headphones
  • Sensory integration therapy - A treatment for motor and sensory motor problems typically administered by occupational therapists
  • Exercise and physical therapy - Exercise is often therapeutic for individuals with autistic disorder; a regular program of activity prescribed by a physical therapist may be helpful

In addition, social skills training helps some children with autism spectrum disorder, including those with comorbid anxiety disorders.[5] Children with autism spectrum disorder and comorbid attention deficit hyperactivity disorder may not benefit from social skills training.[5]

In a 2-year randomized, controlled trial, children who received the Early Start Denver Model (ESDM), a comprehensive developmental behavioral intervention for improving outcomes of toddlers diagnosed with autism spectrum disorder, showed significant improvements in IQ, adaptive behavior, and autism diagnosis compared with children who received intervention commonly available in the community.[122] A follow-up electroencephalographic study showed normalized patterns of brain activity in the ESDM group.[123]

In contrast, a 12-week study of parent-delivered ESDM intervention found no effect on child outcomes compared with usual community treatment. However, starting intervention at an earlier age and providing a greater number of intervention hours both related to the degree of improvement in children's behavior.[124]

Previous
Next

Diet

When compared with their typically developing (TD) peers, children with ASD are significantly more likely to experience GI problems and food allergies. According to one study, children with ASD were 6 to 8 times more likely to report frequent gas/bloating, constipation, diarrhea, and sensitivity to foods than TD children. Researchers also discovered a link between GI symptoms and maladaptive behavior in children with ASD. When these children had frequent GI symptoms, they showed worse irritability, social withdrawal, stereotypy, and hyperactivity scores compared with those without frequent symptoms.[125, 126]

Individuals with autistic disorder or a related condition need 3 well-balanced meals daily. Dietary consultation may be useful to evaluate the benefits of special diets, including those lacking gluten and casein. Vitamin B-6 and magnesium are among the vitamins and minerals hypothesized to help some patients.[127]

In a randomized, double-blind, placebo-controlled trial, 3 months of treatment with a vitamin/mineral supplement produced statistically significant improvement in the nutritional and metabolic status of children with autism. In addition, the supplement group had significantly greater improvements than did the placebo group in its Parental Global Impressions-Revised (PGI-R) Average Change scores.[128]

Previous
Next

Pharmacologic Treatment

Although 70% of children with autism spectrum disorder receive medications, only limited evidence exists that the beneficial effects outweigh the adverse effects.[129] No pharmacologic agent is effective in the treatment of the core behavioral manifestations of autistic disorder, but drugs may be effective in treating associated behavioral problems and comorbid disorders.[130, 131]

The second-generation antipsychotic agents risperidone and aripiprazole provide beneficial effects on challenging and repetitive behaviors in children with autism spectrum disorder, although these patients may experience significant adverse effects.[132] Risperidone and aripiprazole have been approved by the US Food and Drug Administration (FDA) for irritability associated with autistic disorder. The second-generation antipsychotic agent ziprasidone may help to control aggression, irritability, and agitation.[133]

Serotonergic drugs are reportedly beneficial for improving behavior in autism. Hyperactivity often improves with methylphenidate therapy.

Additionally, treatments may be indicated for an underlying condition. For example, children with biotin-responsive infantile encephalopathy improve with the addition of biotin.

SSRIs

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for children with autism and related conditions. Beneficial effects on children and adolescents with autism and other pervasive developmental disorders have been reported with fluoxetine,[134] escitalopram,[135] and citalopram[136, 137] .

On the other hand, a multicenter, randomized, controlled trial by King and colleagues in 149 children with autism spectrum disorders found no difference between citalopram and placebo among children rated as much improved or very much improved. Participants in the treatment arm received liquid citalopram daily for 12 weeks at a mean maximum daily dose of 16.5 mg (maximum 20 mg). Nearly all the citalopram recipients reported adverse effects (eg, impulsiveness, hyperactivity, diarrhea).[138]

Serotonin syndrome

Children with autistic disorder are at risk of developing a serotonin syndrome when treated with serotonergic agents. Therefore, children who are treated with serotonergic agents should be evaluated at baseline before beginning treatment and then regularly evaluated for symptoms of a serotonin syndrome using the serotonin syndrome checklist. See the image below for a printable version.

Serotonin syndrome checklist. Serotonin syndrome checklist.

Adverse effects and treatment efficacy

Children with autistic disorder appear sensitive to medication and may experience serious adverse effects that outweigh any beneficial effects. For example, children may develop catatonia when treated with haloperidol and other traditional neuroleptics.[139, 140] Additionally, Kem et al noted priapism in an adolescent with autism who was treated with trazodone.[141]

Practice guidelines from the American Academy of Pediatrics stress the importance of having some quantifiable means of assessing the efficacy of medication used for the treatment of children with autism. Validated, treatment-sensitive rating scales that have been used in clinical practice to measure the effects of treatment on maladaptive behavior include the Clinical Global Impression Scale, the Aberrant Behavior Checklist, and the Nisonger Child Behavior Rating Form.[142]

Previous
Next

Experimental Approaches

Various interventions, including chiropractic manipulations, are reported to help with autistic disorder. The results of individual case reports, however, cannot be generalized to the overall autistic population; scientific research is needed to investigate whether treatments truly are generally helpful.

Secretin therapy

Several anecdotal reports suggested that secretin, a gastrointestinal hormone that may function as a neurotransmitter, was an effective intervention for the symptoms of autism. This led to several scientific studies of secretin for children with autism spectrum disorders.[143, 144, 145] However, 2 reviews of these trials failed to demonstrate that secretin had a beneficial effect on these children.[146, 147]

Hyperbaric oxygen therapy

Beneficial effects from hyperbaric oxygen therapy have been reported in 6 patients with autism. The risks of this procedure must be weighed against the benefits for individual patients. Controlled clinical trials and other studies are needed to confirm the potential value of this intervention.

Intranasal oxytocin

Research suggests that administration of a single intranasal dose of the hormone oxytocin increases activity in brain regions associated with reward, social perception, and emotional awareness and temporarily improves social information processing in children with autism spectrum disorder (ASD).[148, 149]

In the study of 17 high-functioning children and adolescents with ASD, brain centers associated with reward and emotion recognition responded more during social tasks when children received oxytocin instead of a placebo.

Although behavioral studies in children and adults suggest that a single dose of intranasal oxytocin improves social interaction and comprehension of affective speech, results from clinical trials examining the effect of daily administration of the drug have been mixed.

Previous
Next

Specialist Resources

Children with autism and related conditions typically benefit from intensive, thorough evaluation performed by experienced professionals. Intensive diagnostic evaluation and treatment are accomplished quickly and effectively by well-trained clinicians at well-staffed centers. Valuable resources are listed below.

Division of Developmental and Behavioral Pediatrics

Pediatric Ambulatory Center

University of Maryland Medical Center

700 West Lombard St

Baltimore, MD

Phone: 410-328-5437

Developmental Disabilities Clinic

Child Study Center

Yale University School of Medicine

230 South Frontage Rd

PO Box 207900

New Haven, CT 06520-7900

Phone: 203-785-2510 (For appointments, call 203-785-2874.)

Fax: 203-737-4197

Developmental Disorders Clinic

The Harris Center for Developmental Studies

Section of Child and Adolescent Psychiatry

Department of Psychiatry

The University of Chicago

5841 South Maryland Ave MC3077

Chicago, IL 60637

Seaver Autism Research Center

Department of Psychiatry

Mount Sinai School of Medicine, Box 1230

One Gustave L Levy Place

New York, NY 10029-6574

Phone: 212-241-2994

Bellevue Hospital Center

462 First Ave

New York, NY 10016-9103

Phone: 212-562-4504

Center for Autism and Related Disorders

Kennedy Krieger Institute

Pierce Building, Third Floor

3825 Greenspring Avenue

Baltimore, MD 21211

Phone: 410-404-6252

Fax: 443-923-7695

Division of Child Psychiatry

New York State Psychiatric Institute, Room 2521

722 West 168th St

New York, NY 10032

Phone: 212-543-5280, 212-543-6782, 212-579-5557

Fax: 212-543-5966

Division of Child and Adolescent Psychiatry

Department of Psychiatry

University of California at Los Angeles

760 Westwood Plaza, Room 48-270

Los Angeles, CA 90095

Phone: 310-825-0470

Fax: 310-206-4446

Medical Investigation of Neurodevelopmental Disorders (MIND) Institute

University of California Davis Medical Center

4860 Y Street, Room 3020

Sacramento, CA 95817

Phone (toll-free): 888-883-0961

Phone: 916-734-5153

Strong Center for Developmental Disabilities

Department of Pediatrics

Children's Hospital at Strong

University of Rochester Medical Center

601 Elmwood Ave

Rochester, NY 14642

Phone: 716-275-2100

Previous
Next

Consultations

Neuropsychological consultation can be helpful to assess intelligence. Deficits in simple and complex problem-solving tasks (verbal and nonverbal), are likely to be demonstrated on the following tests:

  • Wisconsin Card Sorting Test
  • Trail Making Test
  • Stanford-Binet Intelligence Test

Other consultations include the following:

  • Ophthalmologic consultation - May be indicated to rule out a treatable visual deficit; special lenses are reported to help some individuals with autistic disorder
  • Neurologic consultation with a movement disorder specialist - Indicated to evaluate tics and other movement disorders when present
  • Infectious disease consultation - May be helpful to rule out bacterial or fungal infections
  • Metabolic consultation - May help to identify any deficiencies
  • Immunologic consultation - May be useful to rule out immune abnormalities; the possible benefits of experimental treatments, such as intravenous (IV) immunoglobulin therapy, must be weighed against the risks of experimental treatments
  • Otolaryngologic consultation - May be indicated to rule out deficits in the auditory apparatus; additionally, audiography is indicated to rule out hearing deficits
Previous
 
 
Contributor Information and Disclosures
Author

James Robert Brasic, MD, MPH Assistant Professor, Russell H Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine, Johns Hopkins University School of Medicine; Active Staff, Department of Radiology and Radiological Science, Division of Nuclear Medicine, Johns Hopkins Hospital; Courtesy Staff, Department of Radiology, Johns Hopkins Bayview Medical Center

James Robert Brasic, MD, MPH is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, American Academy of Neurology, International Parkinson and Movement Disorder Society

Disclosure: Received royalty from Medscape for other; Received royalty from Neuroscience-Net, LLC for other; Received grant/research funds from National Institutes of Health for other.

Chief Editor

Caroly Pataki, MD Health Sciences Clinical Professor of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, David Geffen School of Medicine

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Acknowledgements

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Acknowledgments

This research is supported by the Essel Foundation, the Brain and Behavior Research Foundation (NARSAD), the Tourette Syndrome Association Inc, the National Institutes of Health, the Department of Psychiatry of Bellevue Hospital Center, and the New York University School of Medicine. The cooperation of the Health and Hospitals Corporation of the City of New York is gratefully acknowledged.

The author also gratefully acknowledges the technical assistance in the preparation of the video portions of this article of the Digital Media Center at the Skirball Institute of Biomolecular Medicine at the New York University Medical Center.

References
  1. [Guideline] Filipek PA, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000 Aug;55(4):468-79. Reaffirmed July 2010. [Full Text].

  2. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA. 2003 Jul 16. 290(3):337-44. [Medline].

  3. Aylward EH, Minshew NJ, Field K, Sparks BF, Singh N. Effects of age on brain volume and head circumference in autism. Neurology. 2002 Jul 23. 59(2):175-83. [Medline].

  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th Edition. Washington, DC: American Psychiatric Association; 2013:

  5. Antshel KM, Polacek C, McMahon M, Dygert K, Spenceley L, Dygert L, et al. Comorbid ADHD and anxiety affect social skills group intervention treatment efficacy in children with autism spectrum disorders. J Dev Behav Pediatr. 2011 Jul-Aug. 32(6):439-46. [Medline].

  6. Marshall BL, Napolitano DA, McAdam DB, Dunleavy III JJ, Tessing JL, Varrell J. Venlafaxine and increased aggression in a female with autism. J Am Acad Child Adolesc Psychiatry. 2003 Apr. 42(4):383-4. [Medline].

  7. Teitelbaum P, Teitelbaum O, Nye J, Fryman J, Maurer RG. Movement analysis in infancy may be useful for early diagnosis of autism. Proc Natl Acad Sci U S A. 1998 Nov 10. 95(23):13982-7. [Medline]. [Full Text].

  8. Brasic JR, Holland JA. Reliable classification of case-control studies of autistic disorder and obstetric complications. Journal of Developmental and Physical Disabilities. 2006;18:355-381:

  9. Brasic JR, Holland JA. A qualitative and quantitative review of obstetric complications and autistic disorder. Journal of Developmental and Physical Disabilities. 2007;19:337-364:

  10. Brasic JR, Holland JA, Alexander M. The increased likelihood of obstetric complications in autistic disorder [abstract]. Southern Medical Journal. 2003;96 (10 supplement):S34:

  11. Fatemi SH, Earle J, Kanodia R, Kist D, Emamian ES, Patterson PH, et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell Mol Neurobiol. 2002 Feb. 22(1):25-33. [Medline].

  12. Gutierrez GC, Smalley SL, Tanguay PE. Autism in tuberous sclerosis complex. J Autism Dev Disord. 1998 Apr. 28(2):97-103. [Medline].

  13. Court finds no Vaccines-autism link. Hum Vaccin. 2010 May 14. 6(5):[Medline].

  14. Brauser D. No Evidence Multiple Vaccines Raise Autism Risk, CDC Says. Medscape Medical News. Available at http://www.medscape.com/viewarticle/781670. Accessed: April 3, 2013.

  15. DeStefano F, Price CS, Weintraub ES. Increasing Exposure to Antibody-Stimulating Proteins and Polysaccharides in Vaccines Is Not Associated with Risk of Autism. J Peds. March 2013.

  16. Hammer LD, Curry ES, Harlor AD, Laughlin JJ, Leeds AJ, Lessin HR, et al. Increasing immunization coverage. Pediatrics. 2010 Jun. 125(6):1295-304. [Medline].

  17. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook EH Jr, Dawson G, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000 Aug 22. 55(4):468-79. [Medline].

  18. Brauser D. New Practice Guidelines for Autism. Medscape Medical News. Available at http://www.medscape.com/viewarticle/819935. Accessed: February 4, 2014.

  19. Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2014 Feb. 53(2):237-57. [Medline].

  20. Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA. 2011 Nov 9. 306(18):2001-10. [Medline].

  21. Davenport L. Measuring thoughts' accurately detects autism. Medscape Medical News. December 3, 2014. [Full Text].

  22. Just MA, Cherkassky VL, Buchweitz A, Keller TA, Mitchell TM. Identifying autism from neural representations of social interactions: neurocognitive markers of autism. PLoS One. 2014. 9(12):e113879. [Medline]. [Full Text].

  23. Hughes JR. Autism: the first firm finding = underconnectivity?. Epilepsy Behav. 2007 Aug. 11(1):20-4. [Medline].

  24. Ecker C, Suckling J, Deoni SC, Lombardo MV, Bullmore ET, Baron-Cohen S, et al. Brain anatomy and its relationship to behavior in adults with autism spectrum disorder: a multicenter magnetic resonance imaging study. Arch Gen Psychiatry. 2012 Feb. 69(2):195-209. [Medline].

  25. Brasic JR, Mohamed M. Human brain imaging of autism spectrum disorders. In: Seeman P, Madras B, Eds. Imaging of the Human Brain in Health and Disease. Neuroscience-Net, LLC, 2012. [Full Text].

  26. NIH press release. Disorganized cortical patches suggest prenatal origin of autism. Available at http://www.nih.gov/news/health/mar2014/nimh-27.htm. Accessed: April 1, 2014.

  27. Stoner R, Chow ML, Boyle MP, Sunkin SM, Mouton PR, Roy S, et al. Patches of disorganization in the neocortex of children with autism. N Engl J Med. 2014 Mar 27. 370(13):1209-19. [Medline].

  28. Carmody DP, Lewis M. Regional white matter development in children with autism spectrum disorders. Dev Psychobiol. 2010 Dec. 52(8):755-63. [Medline].

  29. Cauda F, Geda E, Sacco K, D'Agata F, Duca S, Geminiani G, et al. Grey matter abnormality in autism spectrum disorder: an activation likelihood estimation meta-analysis study. J Neurol Neurosurg Psychiatry. 2011 Dec. 82(12):1304-13. [Medline].

  30. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem. 2010 Sep 1. 114(5):1414-23. [Medline]. [Full Text].

  31. Chugani DC. Neuroimaging and neurochemistry of autism. Pediatr Clin North Am. 2012 Feb. 59(1):63-73, x. [Medline].

  32. Pennesi CM, Klein LC. Effectiveness of the gluten-free, casein-free diet for children diagnosed with autism spectrum disorder: based on parental report. Nutr Neurosci. 2012 Mar. 15(2):85-91. [Medline].

  33. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in "low-functioning" autistic children: a pilot study. Biol Psychiatry. 1999 Aug 1. 46(3):420-4. [Medline].

  34. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5. 141B(8):947-56. [Medline]. [Full Text].

  35. Oliveira G, Diogo L, Grazina M, Garcia P, Ataíde A, Marques C, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol. 2005 Mar. 47(3):185-9. [Medline].

  36. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004 Dec. 34(6):615-23. [Medline].

  37. Larsson HJ, Eaton WW, Madsen KM, Vestergaard M, Olesen AV, Agerbo E, et al. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005 May 15. 161(10):916-25; discussion 926-8. [Medline].

  38. Lawler CP, Croen LA, Grether JK, Van de Water J. Identifying environmental contributions to autism: provocative clues and false leads. Ment Retard Dev Disabil Res Rev. 2004. 10(4):292-302. [Medline].

  39. Constantino JN, Zhang Y, Frazier T, Abbacchi AM, Law P. Sibling recurrence and the genetic epidemiology of autism. Am J Psychiatry. 2010 Nov. 167(11):1349-56. [Medline]. [Full Text].

  40. Glasson EJ, Bower C, Petterson B, de Klerk N, Chaney G, Hallmayer JF. Perinatal factors and the development of autism: a population study. Arch Gen Psychiatry. 2004 Jun. 61(6):618-27. [Medline].

  41. Hughes S. Prenatal Valproate Exposure Linked to Autism. Medscape Medical News. Available at http://www.medscape.com/viewarticle/803034. Accessed: May 2, 2013.

  42. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013 Apr 24. 309(16):1696-703. [Medline].

  43. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011 Nov. 68(11):1104-12. [Medline].

  44. Brooks M. Autism Risk Linked to Maternal Thyroid Dysfunction. Available at http://www.medscape.com/viewarticle/809718. Accessed: August 27, 2013.

  45. Román GC, Ghassabian A, Bongers-Schokking JJ, Jaddoe VW, Hofman A, de Rijke YB, et al. Association of gestational maternal hypothyroxinemia and increased autism risk. Ann Neurol. 2013 Aug 13. [Medline].

  46. Ozonoff S, Young GS, Carter A, Messinger D, Yirmiya N, Zwaigenbaum L, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics. 2011 Sep. 128(3):e488-95. [Medline]. [Full Text].

  47. Abrahams BS, Geschwind DH. Connecting genes to brain in the autism spectrum disorders. Arch Neurol. 2010 Apr. 67(4):395-9. [Medline].

  48. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008 May. 9(5):341-55. [Medline]. [Full Text].

  49. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011 Nov. 68(11):1095-102. [Medline].

  50. Gillberg C, Cederlund M. Asperger syndrome: familial and pre- and perinatal factors. J Autism Dev Disord. 2005 Apr. 35(2):159-66. [Medline].

  51. Merritt JL 2nd, Jalal SM, Barbaresi WJ, Babovic-Vuksanovic D. 14q32.3 deletion syndrome with autism. Am J Med Genet A. 2005 Feb 15. 133A(1):99-100. [Medline].

  52. Liu XQ, Georgiades S, Duku E, Thompson A, Devlin B, Cook EH, et al. Identification of genetic loci underlying the phenotypic constructs of autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2011 Jul. 50(7):687-696.e13. [Medline].

  53. Jorde LB, Hasstedt SJ, Ritvo ER, Mason-Brothers A, Freeman BJ, Pingree C, et al. Complex segregation analysis of autism. Am J Hum Genet. 1991 Nov. 49(5):932-8. [Medline]. [Full Text].

  54. Schaefer GB, Lutz RE. Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders. Genet Med. 2006 Sep. 8(9):549-56. [Medline].

  55. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007 Jan. 39(1):25-7. [Medline]. [Full Text].

  56. Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet. 2008 Jun. 16(6):666-72. [Medline].

  57. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A. 2007 Sep 25. 104(39):15537-42. [Medline]. [Full Text].

  58. Curatolo P, Porfirio MC, Benedetti S, Giana G, Manzi B. [Autismo.]. Minerva Pediatr. 2008/10;60(5):846-848:

  59. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008 Aug 23. 372(9639):657-68. [Medline].

  60. Roberts EM, English PB, Grether JK, Windham GC, Somberg L, Wolff C. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. Environ Health Perspect. 2007 Oct. 115(10):1482-9. [Medline]. [Full Text].

  61. Samson K. CDC-backed study suggests possible link between autistic disorders, maternal perticide exposure in California. Neurology Today. September 2007;7:7:

  62. Hackethal V. More Evidence Links Autism to Air Pollution. Medscape Medical News. Available at http://www.medscape.com/viewarticle/833653. Accessed: October 24, 2014.

  63. Evelyn Talbott, Lynne Marshall, Judith Rager, Vincent Arena, Ravi Sharma. The Association of National Air Toxics Assessment Exposures and the Risk of Childhood Autism Spectrum Disorder: A Case Control Study. American Association for Aerosol Research. Available at http://aaarabstracts.com/2014/viewabstract.php?pid=599. Accessed: October 24, 2014.

  64. Sandin S, Hultman CM, Kolevzon A, Gross R, MacCabe JH, Reichenberg A. Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2012 May. 51(5):477-486.e1. [Medline].

  65. Hultman CM, Sandin S, Levine SZ, Lichtenstein P, Reichenberg A. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry. 2011 Dec. 16(12):1203-12. [Medline].

  66. Rapin I, Tuchman RF. What is new in autism?. Curr Opin Neurol. 2008 Apr. 21(2):143-9. [Medline].

  67. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry. 2005 Jun. 46(6):572-9. [Medline].

  68. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 1999 Jun 12. 353(9169):2026-9. [Medline].

  69. Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007 Sep 27. 357(13):1281-92. [Medline].

  70. Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 2010 Feb 6. 375(9713):445. [Medline].

  71. Dobbs M. What the autism studies show isn't reflected in what the candidates say. The Washington Post. April 22, 2008;A: A8:

  72. Blaxill MF. What's going on? The question of time trends in autism. Public Health Rep. 2004 Nov-Dec. 119(6):536-51. [Medline]. [Full Text].

  73. Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics. 2005 Mar. 115(3):e277-82. [Medline].

  74. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc Med. 2005 Jan. 159(1):37-44. [Medline].

  75. Rutter M. Aetiology of autism: findings and questions. J Intellect Disabil Res. 2005 Apr. 49:231-8. [Medline].

  76. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatr. 2005 Jan. 94(1):2-15. [Medline].

  77. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014 Mar 28. 63 (2):1-21. [Medline].

  78. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011 Sep. 168(9):904-12. [Medline].

  79. Kurita H. [Current status of autism studies]. Seishin Shinkeigaku Zasshi. 2001. 103(1):64-75. [Medline].

  80. Bailey A, Bolton P, Butler L, Le Couteur A, Murphy M, Scott S, et al. Prevalence of the fragile X anomaly amongst autistic twins and singletons. J Child Psychol Psychiatry. 1993 Jul. 34(5):673-88. [Medline].

  81. Chudley AE, Hagerman RJ. Fragile X syndrome. J Pediatr. 1987 Jun. 110(6):821-31. [Medline].

  82. Cohen IL, Sudhalter V, Pfadt A, Jenkins EC, Brown WT, Vietze PM. Why are autism and the fragile-X syndrome associated? Conceptual and methodological issues. Am J Hum Genet. 1991 Feb. 48(2):195-202. [Medline]. [Full Text].

  83. Einfeld SL. Autism and the fragile X syndrome. Am J Med Genet. 1988 May-Jun. 30(1-2):237-8. [Medline].

  84. Fisch GS, Cohen IL, Jenkins EC, Brown WT. Screening developmentally disabled male populations for fragile X: the effect of sample size. Am J Med Genet. 1988 May-Jun. 30(1-2):655-63. [Medline].

  85. Reiss AL, Freund L. Fragile X syndrome, DSM-III-R, and autism. J Am Acad Child Adolesc Psychiatry. 1990 Nov. 29(6):885-91. [Medline].

  86. Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatr. 2011 Jun. 32(5):351-60. [Medline].

  87. Mahoney A, Poling A. Sexual Abuse Prevention for People with Severe Developmental Disabilities. J of Developmental and Physical Disabilities. May 2011;23(4):369-76:

  88. Anderson C, Law JK, Daniels A, Rice C, Mandell DS, Hagopian L, et al. Occurrence and family impact of elopement in children with autism spectrum disorders. Pediatrics. 2012 Nov. 130(5):870-7. [Medline].

  89. Baron-Cohen S, Allen J, Gillberg C. Can autism be detected at 18 months? The needle, the haystack, and the CHAT. Br J Psychiatry. Dec 1992;161:839-43:[Medline].

  90. Baron-Cohen S, Cox A, Baird G, Swettenham J, Nightingale N, Morgan K, et al. Psychological markers in the detection of autism in infancy in a large population. Br J Psychiatry. 1996 Feb. 168(2):158-63. [Medline].

  91. Lee MS, Kim JI, Ernst E. Massage therapy for children with autism spectrum disorders: a systematic review. J Clin Psychiatry. 2011 Mar. 72(3):406-11. [Medline].

  92. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 Oct. 24(5):659-85. [Medline].

  93. Liptak GS, Kennedy JA, Dosa NP. Social Participation in a Nationally Representative Sample of Older Youth and Young Adults With Autism. J Dev Behav Pediatr. 2011 Apr 15. [Medline].

  94. Allison C, Auyeung B, Baron-Cohen S. Toward brief "Red Flags" for autism screening: The Short Autism Spectrum Quotient and the Short Quantitative Checklist for Autism in toddlers in 1,000 cases and 3,000 controls [corrected]. J Am Acad Child Adolesc Psychiatry. 2012 Feb. 51(2):202-212.e7. [Medline].

  95. Allison C, Baron-Cohen S, Wheelwright S, Charman T, Richler J, Pasco G, et al. The Q-CHAT (Quantitative CHecklist for Autism in Toddlers): a normally distributed quantitative measure of autistic traits at 18-24 months of age: preliminary report. J Autism Dev Disord. 2008 Sep. 38(8):1414-25. [Medline].

  96. Auyeung B, Baron-Cohen S, Wheelwright S, Allison C. The Autism Spectrum Quotient: Children's Version (AQ-Child). J Autism Dev Disord. 2008 Aug. 38(7):1230-40. [Medline].

  97. Baron-Cohen S, Hoekstra RA, Knickmeyer R, Wheelwright S. The Autism-Spectrum Quotient (AQ)--adolescent version. J Autism Dev Disord. 2006 Apr. 36(3):343-50. [Medline].

  98. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord. 2001 Feb. 31(1):5-17. [Medline].

  99. Fombonne E, Rogé B, Claverie J, Courty S, Frémolle J. Microcephaly and macrocephaly in autism. J Autism Dev Disord. 1999 Apr. 29(2):113-9. [Medline].

  100. National Center for Health Statistics. International Classification of Diseases (ICD-9-CM), 9th Revision, Clinical Modification. 4th Edition. Los Angeles, CA: Practice Management Information Corporation (PMIC); 1993:

  101. Canal-Bedia R, García-Primo P, Martín-Cilleros MV, Santos-Borbujo J, Guisuraga-Fernández Z, Herráez-García L, et al. Modified checklist for autism in toddlers: cross-cultural adaptation and validation in Spain. J Autism Dev Disord. 2011 Oct. 41(10):1342-51. [Medline].

  102. [Guideline] Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Use of motor and self-care assessment tools for children with autism spectrum disorder (ASD). 2009 Jul. [Full Text].

  103. Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Use of sensory assessment tools with children diagnosed with autism spectrum disorder (ASD). 2009 Mar. [Full Text].

  104. [Guideline] New York State Department of Health, Division of Family Health, Bureau of Early Intervention. Clinical Practice Guideline: Quick Reference Guide. Autism/Pervasive Developmental Disorders, Assessment and Intervention for Young Children (Age 0-3 Years). Reprinted 2009. [Full Text].

  105. Lord C, Petkova E, Hus V, Gan W, Lu F, Martin DM, et al. A multisite study of the clinical diagnosis of different autism spectrum disorders. Arch Gen Psychiatry. 2012 Mar. 69(3):306-13. [Medline].

  106. Sahota PK, Miles JH, Wang CH. Sleep disorders in children with autism. Neurology. 1997;48 (3):A258:

  107. Hashimoto T, Tayama M, Miyazaki M, Murakawa K, Shimakawa S, Yoneda Y, et al. Brainstem involvement in high functioning autistic children. Acta Neurol Scand. 1993 Aug. 88(2):123-8. [Medline].

  108. Hashimoto T, Tayama M, Murakawa K, Yoshimoto T, Miyazaki M, Harada M, et al. Development of the brainstem and cerebellum in autistic patients. J Autism Dev Disord. 1995 Feb. 25(1):1-18. [Medline].

  109. Filipek PA. Quantitative magnetic resonance imaging in autism: the cerebellar vermis. Curr Opin Neurol. 1995 Apr. 8(2):134-8. [Medline].

  110. Via E, Radua J, Cardoner N, Happé F, Mataix-Cols D. Meta-analysis of gray matter abnormalities in autism spectrum disorder: should Asperger disorder be subsumed under a broader umbrella of autistic spectrum disorder?. Arch Gen Psychiatry. 2011 Apr. 68(4):409-18. [Medline].

  111. Eyler LT, Pierce K, Courchesne E. A failure of left temporal cortex to specialize for language is an early emerging and fundamental property of autism. Brain. 2012 Mar. 135:949-60. [Medline]. [Full Text].

  112. Sundaram SK, Kumar A, Makki MI, Behen ME, Chugani HT, Chugani DC. Diffusion tensor imaging of frontal lobe in autism spectrum disorder. Cereb Cortex. 2008 Nov. 18(11):2659-65. [Medline]. [Full Text].

  113. Barnea-Goraly N, Lotspeich LJ, Reiss AL. Similar white matter aberrations in children with autism and their unaffected siblings: a diffusion tensor imaging study using tract-based spatial statistics. Arch Gen Psychiatry. 2010 Oct. 67(10):1052-60. [Medline].

  114. Jou RJ, Mateljevic N, Kaiser MD, Sugrue DR, Volkmar FR, Pelphrey KA. Structural neural phenotype of autism: preliminary evidence from a diffusion tensor imaging study using tract-based spatial statistics. AJNR Am J Neuroradiol. 2011 Oct. 32(9):1607-13. [Medline].

  115. Heh CW, Smith R, Wu J, Hazlett E, Russell A, Asarnow R, et al. Positron emission tomography of the cerebellum in autism. Am J Psychiatry. 1989 Feb. 146(2):242-5. [Medline].

  116. Chiron C, Leboyer M, Leon F, Jambaqué I, Nuttin C, Syrota A. SPECT of the brain in childhood autism: evidence for a lack of normal hemispheric asymmetry. Dev Med Child Neurol. 1995 Oct. 37(10):849-60. [Medline].

  117. Malow BA. Sleep deprivation and epilepsy. Epilepsy Curr. 2004 Sep-Oct. 4(5):193-5. [Medline]. [Full Text].

  118. McGuire K, Erickson C, Gabriels RL, Kaplan D, Mazefsky C, McGonigle J, et al. Psychiatric Hospitalization of Children With Autism or Intellectual Disability: Consensus Statements on Best Practices. J Am Acad Child Adolesc Psychiatry. 2015 Dec. 54 (12):969-71. [Medline].

  119. [Guideline] Luiselli JK, Bass JD, Whitcomb SA. Teaching applied behavior analysis knowledge competencies to direct-care service providers: outcome assessment and social validation of a training program. Behav Modif. 2010 Sep. 34(5):403-14. [Medline].

  120. [Guideline] Carr JE, Fox EJ. Using video technology to disseminate behavioral procedures: a review of Functional Analysis: a Guide for Understanding Challenging Behavior (DVD). J Appl Behav Anal. 2009 Winter. 42(4):919-23. [Medline]. [Full Text].

  121. Ganz JB, Davis JL, Lund EM, Goodwyn FD, Simpson RL. Meta-analysis of PECS with individuals with ASD: investigation of targeted versus non-targeted outcomes, participant characteristics, and implementation phase. Res Dev Disabil. 2012 Mar-Apr. 33(2):406-18. [Medline].

  122. Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics. 2010 Jan. 125(1):e17-23. [Medline].

  123. Dawson G, Jones EJ, Merkle K, Venema K, Lowy R, Faja S, et al. Early behavioral intervention is associated with normalized brain activity in young children with autism. J Am Acad Child Adolesc Psychiatry. 2012 Nov. 51(11):1150-9. [Medline].

  124. Rogers SJ, Estes A, Lord C, Vismara L, Winter J, Fitzpatrick A, et al. Effects of a Brief Early Start Denver Model (ESDM)-Based Parent Intervention on Toddlers at Risk for Autism Spectrum Disorders: A Randomized Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2012 Oct. 51(10):1052-65. [Medline]. [Full Text].

  125. Brooks M. GI Troubles Common, Linked to Negative Behaviors in Autism. Medscape Medical News. Available at http://www.medscape.com/viewarticle/814364.. Accessed: November 26, 2013.

  126. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal Problems in Children with Autism, Developmental Delays or Typical Development. J Autism Dev Disord. 2013 Nov 6. [Medline].

  127. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006 Mar. 19(1):53-62. [Medline].

  128. Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr. 2011 Dec 12. 11:111. [Medline]. [Full Text].

  129. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2007 Jun. 17(3):348-55. [Medline].

  130. Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013 Nov. 132(5):833-40. [Medline].

  131. Brauser D. Psychotropics Still Commonly Prescribed for Autism. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/812982. Accessed: November 2, 2013.

  132. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011 May. 127(5):e1312-21. [Medline].

  133. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002 Aug. 41(8):921-7. [Medline].

  134. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005 Mar. 30(3):582-9. [Medline].

  135. Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2005 Apr. 44(4):343-8. [Medline].

  136. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr. 2003 Apr. 24(2):104-8. [Medline].

  137. Couturier JL, Nicolson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2002 Fall. 12(3):243-8. [Medline].

  138. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009 Jun. 66(6):583-90. [Medline].

  139. Brasic JR, Zagzag D, Kowalik S, Prichep L, John ER, Barnett JY, et al. Clinical manifestations of progressive catatonia. Ger J Psychiatr. 2000. 3 (2):13-24. [Full Text].

  140. Brasic JR, Zagzag D, Kowalik S, Prichep L, John ER, Liang HG, et al. Progressive catatonia. Psychol Rep. 1999. 84 (1):239-46.

  141. Kem DL, Posey DJ, McDougle CJ. Priapism associated with trazodone in an adolescent with autism. J Am Acad Child Adolesc Psychiatry. 2002 Jul. 41(7):758. [Medline].

  142. [Guideline] American Academy of Pediatrics. Management of Children With Autism Spectrum Disorder. Pediatrics. 2007 Nov;120(5):1183-1215. Available at http://pediatrics.aappublications.org/content/120/5/1162.full.

  143. Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses. 2007. 68(6):1208-27. [Medline].

  144. Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006. 67(2):216-28. [Medline].

  145. Rossignol DA, Rossignol LW, James SJ, Melnyk S, Mumper E. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr. 2007 Nov 16. 7:36. [Medline]. [Full Text].

  146. Krishnaswami S, McPheeters ML, Veenstra-Vanderweele J. A systematic review of secretin for children with autism spectrum disorders. Pediatrics. 2011 May. 127(5):e1322-5. [Medline]. [Full Text].

  147. Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012 Apr 18. 4:CD003495. [Medline].

  148. Cassels C. Oxytocin 'Normalizes' Social Deficits in Kids With Autism. Medscape Medical News. Available at http://www.medscape.com/viewarticle/817552. Accessed: December 16, 2013.

  149. Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas MV, Eilbott JA, et al. Oxytocin enhances brain function in children with autism. Proc Natl Acad Sci U S A. 2013 Dec 2. [Medline].

  150. Celexa (citalopram hydrobromide) [package insert]. St. Louis, Missouri: Forest Pharmaceuticals, Inc; August, 2011. [Full Text].

  151. US Food and Drug Administration. Celexa (citalopram hydrobromide): Drug safety communication – abnormal heart rhythms associated with high doses. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm269481.htm. Accessed: October 24, 2012.

  152. A Message From APA President Dilip Jeste, M.D., on DSM-5. Available at http://www.psychnews.org/files/DSM-message.pdf. Accessed: December 1, 2012.

  153. American Psychiatric Association. DSM-5 Development, Autism Spectrum Disorder. Proposed Revision. Available at http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=94. Accessed: December 22, 2011.

  154. APA. Autism Spectrum Disorder. Available at http://www.dsm5.org/Documents/Autism%20Spectrum%20Disorder%20Fact%20Sheet.pdf.. Accessed: July 1, 2013.

  155. Brauser D. Abnormal Placentas May Signal Autism Risk. Medscape Medical News. Available at http://www.medscape.com/viewarticle/803331. Accessed: May 14, 2013.

  156. Brauser D. Developmental Delays Detectable in High-risk 1-Year-Olds. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821851. Accessed: March 17, 2014.

  157. Brauser D. Routine Ultrasound Scans May Detect Autism in Utero. Medscape Medical News. Available at http://www.medscape.com/viewarticle/827333. Accessed: July 2, 2014.

  158. Brauser D. Some kids 'age out' of autism. Medscape Medical News. January 23, 2013. Available at http://www.medscape.com/viewarticle/778061. Accessed: January 29, 2013.

  159. Corrigan NM, Shaw DW, Estes AM, Richards TL, Munson J, Friedman SD, et al. Atypical Developmental Patterns of Brain Chemistry in Children With Autism Spectrum Disorder. JAMA Psychiatry. 2013 Jul 31. [Medline].

  160. Fein D, Barton M, Eigsti IM, Kelley E, Naigles L et al. Optimal outcome in individuals with a history of autism. J Child Psychol Psychiatry. 2013 Feb. 54(2):195-205. [Medline]. [Full Text].

  161. Frazier TW, Youngstrom EA, Speer L, Embacher R, Law P, Constantino J, et al. Validation of proposed DSM-5 criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan. 51(1):28-40.e3. [Medline]. [Full Text].

  162. Harrison P. Novel Drug Modifies Core Autism Symptoms in Adults. Medscape Medical News. May 27 2014. [Full Text].

  163. Huerta M, Bishop SL, Duncan A, Hus V, Lord C. Application of DSM-5 Criteria for Autism Spectrum Disorder to Three Samples of Children With DSM-IV Diagnoses of Pervasive Developmental Disorders. . Am J Psychiatry 2012;169:1056-1064. [Full Text].

  164. Mandy WP, Charman T, Skuse DH. Testing the construct validity of proposed criteria for DSM-5 autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan. 51(1):41-50. [Medline].

  165. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009 Nov. 48(11):1110-9. [Medline].

  166. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002 Aug 1. 347(5):314-21. [Medline].

  167. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 Dec. 124(6):1533-40. [Medline].

  168. Ozonoff S, Young GS, Belding A, et al. The Broader Autism Phenotype in Infancy: When Does It Emerge?. J American Academy Child Adolesc Psychiatry. 2014 Jan 23. [Epub ahead of print].

  169. Stetka B, Correll, C. A Guide to DSM-5: Autism Spectrum Disorders. Medscape Medical News. Available at http://www.medscape.com/viewarticle/803884_4. Accessed: July 1, 2013.

  170. Walker CK, Anderson KW, Milano KM, Ye S, Tancredi DJ, Pessah IN, et al. Trophoblast Inclusions Are Significantly Increased in the Placentas of Children in Families at Risk for Autism. Biol Psychiatry. 2013 Apr 22. [Medline].

 
Previous
Next
 
The significance of answers to individual Autism Screening Checklist items is as follows: Item 1- A "yes" occurs in healthy children and children with some pervasive developmental disorders; a "no" occurs in children with autism, Rett syndrome, and other developmental disorders. Item 2 - A "yes" occurs in healthy children, not children with autism. Item 3 - A "yes" occurs in healthy children and children with Asperger syndrome (ie, high-functioning autism); a "no" occurs in children with Rett syndrome; children with autism may elicit a "yes" or a "no"; some children with autism never speak; some children with autism may develop speech normally and then experience a regression with the loss of speech. Item 4 - A "yes" occurs in healthy children and children with Asperger syndrome and some other pervasive developmental disorders; a "no" occurs in children with developmental disorders; children with autism may elicit a "yes" or a "no." Items 5-10 - Scores of "yes" occur in some children with autism and in children with other disorders. Item 11 – A "yes" occurs in healthy children; a "no" occurs in some children with autism and in children with other disorders. Items 12, 13 - Scores of "yes" occur in some children with autism and in children with other disorders. Items 14-19 - Scores of "yes" occur in children with schizophrenia and other disorders, not in children with autism, Asperger syndrome, or other autism spectrum disorders. The higher the total score for items 5-10, 12, and 13 on the Autism Screening Checklist, the more likely the presence of an autism spectrum disorder.
Serotonin syndrome checklist.
Clinicians are advised to videotape the process of verbally explaining the protocol and answering questions. Permission must be explicitly given to perform the procedure and cannot continue until the parents agree. Parents are asked to give permission to complete this protocol. The entire process is videotaped. In this segment, the mother of a healthy, normal control child gives informed consent to participate as a volunteer in a research study of autism. Occasionally, parents decline to give consent, and the procedure must cease. An earlier version of this videotape is in the New York University Medical Library, New York, New York.
A 7-year-old boy with autistic disorder took daily vitamins and no other medications at the time of assessment. The examiner repeated movements of the telephone receiver and tapping on the telephone receiver initially exhibited by the subject. The examiner repeated the subject's actions several times in an attempt to elicit repetition of the movement by the subject. Instead, the subject does not acknowledge the presence of the examiner. He looks away from the examiner. He turns his back to the examiner. The subject spins by rotating on a central vertical axis in his body. He exhibits nonfunctional play with the telephone. He displays frequent finger wiggling and the other hand stereotypies. He frequently vocalizes indecipherable sounds and briefly rocks. He tilts his head and looks out of the corner of his eye for a few seconds. Please note that media file represents a diagnostic assessment of a child. The child is allowed to exhibit the abnormal behaviors to demonstrate those items on a video for confirmation by blind raters. If the child exhibited behaviors danger to himself, such as self-injurious behaviors, or dangerous to other, such as attacking others, then the examiner would intervene to prevent injury to the child and others. The media files does not in any way represent treatment for the disorder.
The examiner may attempt to establish a sequence of taking turns hitting a plate with a block. The examiner says, "My turn," and then taps the plate. The examiner gives the block to the subject and says, "Your turn." The subject may be physically assisted in the activity if the desired response does not occur. The following is a clinical example: A 7-year-old boy with autistic disorder took daily vitamins and no other medications at the time of assessment. The examiner attempted to elicit turn-taking by hitting the plate with a block. The child repeatedly jumps and rotates. He exhibits nonfunctional play with the telephone. He tilts his head and peers out of the corner of his eye. He is interested in the feel of the stick. He exhibits quick hand movements with small toys. When his father and his brother leave the room, the child does not acknowledge their departure. When his father returns to the room, he does not run to greet him. He appears indifferent to the departure and the return of his father. He repeatedly touches the surface of the wooden block. He touches the surface of a furlike cloth. He also places this cloth to his mouth to feel the texture on his lips. He is also fascinated with a string of yarn. He moves the string of yarn up and down and back and forth. This is nonfunctional play with ordinary items. Please note that media file represents a diagnostic assessment of a child. The child is allowed to exhibit the abnormal behaviors to demonstrate those items on a video for confirmation by blind raters. If the child exhibited behaviors danger to himself, such as self-injurious behaviors, or dangerous to other, such as attacking others, then the examiner would intervene to prevent injury to the child and others. The media files does not in any way represent treatment for the disorder.
The following is a clinical example that continues the segment of prior video: A 7-year-old boy with autistic disorder took daily vitamins and no other medications at the time of assessment. He appears indifferent to the departure of his brother from the room. He also does not respond with a greeting when his brother returns. He appears interested in his nonfunctional play. He displays minimal acknowledgment of the departure and return of his brother. In particular, he does not respond to his brother's touching him on the shoulder to greet him. Instead, he demonstrates inappropriate friendliness with the psychologist who is evaluating the procedures. Although he never saw her before this assessment, he suddenly goes to her to kiss her. Please note that media file represents a diagnostic assessment of a child. The child is allowed to exhibit the abnormal behaviors to demonstrate those items on a video for confirmation by blind raters. If the child exhibited behaviors danger to himself, such as self-injurious behaviors, or dangerous to other, such as attacking others, then the examiner would intervene to prevent injury to the child and others. The media files does not in any way represent treatment for the disorder.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.